Search

Displaying results 3101 - 3110 of 10000 in total
  1. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system. … This drug is developed by Ceregene and currently under phase I of clinical trial.

  2. Drug

    Ferrous gluconate

    go.drugbank.com/drugs/DB14488
    ApprovedInvestigational

    Mixtures: FERROZINC - G SURUP, 100 ML, Supravite C 1000Products: LOSFERRON FORT EFERVESAN TABLET, 30 ADET
  3. Drug

    Ocaratuzumab

    go.drugbank.com/drugs/DB17359
    Investigational

    Ocaratuzumab is a humanized monoclonal antibody directed against CD20. It is being investigated for cancers and autoimmune disorders.

    Synonyms: Immunoglobulin G1, anti-(human B-lymphocyte antigen CD20 (B-lymphocyte surface antigen B1, Bp35, leukocyte surface antigen Leu-16, membrane-spanning 4-domains subfamily A member 1))
  4. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Substrates
  5. Indication

    Tick-Borne Encephalitis, European

    go.drugbank.com/conditions/DBCOND0144103
    Drugs: Tick-borne encephalitis vaccine (whole virus, inactivated)
    Synonyms: Encephalitis due to tick-borne encephalitis virus (navigational concept)
  6. Drug

    Vutrisiran

    go.drugbank.com/drugs/DB16699
    ApprovedInvestigational

    [A249010] More than 130 TTR mutations have been identified so far,[A249015] but the most common one is the replacement of valine with methionine at position 30 (Val30Met). … [A249010] TTR mutations lead to the formation of misfolded TTR proteins, which form amyloid fibrils that deposit in different types of tissues.

  7. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    [A230123] _In vitro_ models show that melphalan is 10 to hundreds of times more potent than melphalan. … [A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases.

  8. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high … INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]

  9. Target

    Mucin-16

    go.drugbank.com/bio_entities/BE0002439
    TargetHumans

    Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces

    Polypeptides: Mucin-16Synonyms: MUC-16
  10. Target

    Claudin-16

    go.drugbank.com/bio_entities/BE0009861
    TransporterHumans

    In the thick ascending limb (TAL) of Henle's loop, facilitates sodium paracellular permeability from the interstitial compartment to the lumen, contributing to the lumen-positive transepithelial potential

    Polypeptides: Claudin-16